PNPLA3 and metabolic dysfunction-associated steatotic liver disease: A meta-analysis of 24 studies with a total of 9,195, mostly Caucasian, patients concluded that PNPLA3 I148M is significantly associated with increased risk of advanced fibrosis in individuals with NAFLD (OR: 1.23, 95% CI 1.10–1.37) and of HCC (OR: 1.67, 95% CI 1.27–2.21) in patients with NAFLD (Singal et al., 2014).